Full Breakdown
UK and US Reach Pharmaceutical Tariff Agreement
12/1/2025, 9:21:50 PM
Overview of the Agreement
The United Kingdom and the United States have finalized a deal that maintains zero tariffs on UK pharmaceutical exports to the US for three years. In exchange, the UK will increase its National Health Service (NHS) spending on medicines, marking the first rise in over two decades. This agreement comes after US President Donald Trump threatened to impose tariffs as high as 100% on branded drug imports, which are a significant export for the UK.
Key Terms of the Deal
Under the new agreement, the UK will raise the cost-effectiveness threshold set by the National Institute for Health and Care Excellence (NICE) by 25%, allowing the NHS to spend more on new medicines. The NHS's overall spending on pharmaceuticals is targeted to increase from 0.3% to 0.6% of GDP over the next decade. Additionally, the cap on revenue that drug companies must repay to the NHS will be reduced from over 20% to 15%. This deal is expected to protect UK pharmaceutical exports, valued at approximately £5 billion annually, from potential US tariffs.
Economic Context
Pharmaceuticals accounted for 17.4% of the UK's total goods exports to the US, amounting to £11.1 billion in the year leading up to September. The UK government has emphasized that this agreement positions the UK as a global hub for life sciences, with Business and Trade Secretary Peter Kyle stating it will safeguard jobs and stimulate investment.
Criticism and Opposition
The agreement has faced criticism from various quarters. Liberal Democrat Health Spokesperson Helen Morgan MP described it as a "Trump shakedown of the NHS," arguing that it compromises the health service under pressure from the US administration. Concerns have also been raised about the potential increase in NHS spending, with estimates suggesting an additional £3 billion could be required, which critics argue could detract from funding for other essential services.
Official Statements
US Trade Representative Jamieson Greer remarked that the deal addresses long-standing concerns about the financial burden on American patients, stating, “For too long, American patients have been forced to subsidize prescription drugs in other developed countries.” Meanwhile, UK Science Secretary Liz Kendall asserted that the agreement would ensure UK patients access to innovative medicines more swiftly.
Verbatim Quotes
- “This agreement is a sign of progress and one that creates an environment conducive to our continued presence in the UK," chief executive Chris Boerner said.” — Chris Boerner, CEO of Bristol Myers Squibb
- “Responding to Monday’s announcement, Liberal Democrat Health Spokesperson Helen Morgan MP said: “This is a Trump shakedown of the NHS, and it cannot go ahead.” — Helen Morgan, Liberal Democrat Health Spokesperson
- “The extra cost will need to be fully-funded by the Treasury,” — Sally Gainsbury, Nuffield Trust
What's Next
The agreement is expected to lead to further discussions on the implications for NHS funding and drug pricing strategies in the UK. As the UK navigates its relationship with the US, the government will need to address the concerns raised by critics regarding the sustainability of increased pharmaceutical spending.
